TLDR:
- Tempest Therapeutics major shareholder Versant Venture Capital Vi, L. sold 387,999 shares of the firm’s stock.
- The shares were sold at an average price of $1.10, totaling $426,798.90.
A major shareholder of Tempest Therapeutics, Inc. (NASDAQ:TPST), Versant Venture Capital Vi, L., recently sold 387,999 shares of the company’s stock, with a total value of $426,798.90. This transaction was disclosed in a document filed with the Securities & Exchange Commission. Following this sale, the insider now holds 209,941 shares valued at $230,935.10. Additionally, on August 8th, Versant Venture Capital Vi, L. also sold 400,000 shares of Tempest Therapeutics stock at an average price of $1.35.
As of Tuesday, TPST stock opened at $0.96 with a market cap of $21.26 million and a price-to-earnings ratio of -0.56. The company has a 12-month low of $0.17 and a high of $9.77. Tempest Therapeutics last posted earnings results on August 8th, beating the consensus estimate by $0.05 with a reported earnings per share of ($0.42). Research analysts expect the company to post -1.57 EPS for the current year.
Several major institutional investors, including MayTech Global Investments LLC, Virtu Financial LLC, and Dimensional Fund Advisors LP have recently modified their holdings in TPST. Analysts have rated Tempest Therapeutics stock as a ‘buy,’ with a consensus target price of $20.75. The company is a clinical-stage oncology company focusing on developing small molecule therapeutics to treat various tumors.
